Allogene Therapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALLO and other ETFs, options, and stocks.About ALLO
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.
ALLO Key Statistics
Stock Snapshot
With a market cap of 254.05M, Allogene Therapeutics(ALLO) trades at $1.15. The stock has a price-to-earnings ratio of -0.94.
As of 2025-11-07, Allogene Therapeutics(ALLO) stock has fluctuated between $1.04 and $1.17. The current price stands at $1.15, placing the stock +10.1% above today's low and -1.8% off the high.
The Allogene Therapeutics(ALLO)'s current trading volume is 2.81M, compared to an average daily volume of 2.2M.
During the past year, Allogene Therapeutics(ALLO) stock moved between $0.86 at its lowest and $3.78 at its peak.
During the past year, Allogene Therapeutics(ALLO) stock moved between $0.86 at its lowest and $3.78 at its peak.
ALLO News
“With our unique allogeneic approach to CAR T, the field has the ability to shift from highly personalized, patient-specific therapies to a new era of readily a...